<DOC>
	<DOC>NCT01886794</DOC>
	<brief_summary>Our primary aim in the current study is to determine important tissue differences, including muscle and connective tissue changes, between postmenopausal women and reproductive age women with pelvic floor dysfunction to help develop targeted and noninvasive treatments.</brief_summary>
	<brief_title>Hormonal Status on Blood Flow and Tissue in Pelvic Organ Prolapse</brief_title>
	<detailed_description />
	<mesh_term>Prolapse</mesh_term>
	<mesh_term>Pelvic Organ Prolapse</mesh_term>
	<mesh_term>Pelvic Floor Disorders</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>21 to 70 years of age Stage II or greater pelvic organ prolapse (POP) Individuals electing surgery to treat their POP Willing and able to comply with study procedures Willing and able to provide written informed consent Contraindication for estrogen cream Any medical condition that in the opinion of the investigator would place the subject at increased risk for participation History of connective tissue disease Previous hysterectomy or pelvic organ prolapse surgery Known allergic reaction to any agent required by the protocol Use of hormone therapy in postmenopausal women in the last 90 days Pregnant or lactating females History of prior noncompliance or the presence or history of psychiatric condition that would in the opinion of the investigator make it difficult for the subject to comply with study procedures or follow instructions</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>pelvic floor dysfunction</keyword>
	<keyword>pelvic organ prolapse</keyword>
	<keyword>vaginal estrogen effects</keyword>
</DOC>